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a b s t r a c t
Apolipoprotein E (ApoE) is a vital component of several lipoproteins and plays amajor role in
lipidmetabolism. APOE gene comprises of three alleles determined by two single nucleotide
polymorphisms (rs429358 and rs7412) resulting in the protein isoforms, amongwhich ApoE4
is a conﬁrmed risk factor for Alzheimer's Disease. However, the impact ofAPOE genotypes on
Parkinson's DiseaseDementia (PDD) is still inconclusive. The PDDdiagnostic criteria are very
inconsistent, and could be complemented with genetic factors. Our study covers a total of
237 patients diagnosed with Parkinson's Disease (PD) according to UK PD Brain Bank criteria,
who were classiﬁed as subjects with (PDD, n equals 73) and without (nPDD, n equals 164)
dementia, using neuropsychological assessment tests. TaqMan real-time PCR assays were
used to determine APOE allele. No statistically signiﬁcant differences in APOE alleles
frequencies between nPDD and PDDpatients have been observed. The study results revealed
that the APOE polymorphism is not associated with cognitive status in PD patients.
© 2018 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.1. IntroductionDementia occurs in up to 40% of Parkinson's Disease patients,
which is estimated to be six times more often than among
healthy individuals [1]. The cumulative prevalence is even* Corresponding author at: Department of Pharmacokinetics and Thera
Powstanców Wlkp. 72, 70-111 Szczecin, Poland.
E-mail address: monika-bialecka@post.pl (M. Białecka).
https://doi.org/10.1016/j.pjnns.2018.04.003
0028-3843/© 2018 Published by Elsevier Sp. z o.o. on behalf of Polish Nhigher as at least 80% of PD patients who survivemore than 12
years from the diagnosis will develop dementia [2].
Apolipoprotein E (ApoE) is a vital component of several
lipoproteins and plays a major role in lipid metabolism. The
APOE gene ismapped to chromosome19and comprises of threepeutic Drug Monitoring, Pomeranian Medical University, Szczecin,
eurological Society.
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located in exon 4 at position 3937 (T/C; rs429358) and 4075 (C/T;
rs7412). ApoE3 is the most common isoform, while ApoE2 and
ApoE4 differ from ApoE3 by single amino acid substitution at
position 112 or 158 [3,4]. It has been observed thatAPOE4 allele is
overrepresented among patients affected with late-onset
familialAlzheimer'sDisease (AD).Moreover,APOE4hasadosage
effect on the risk and age at the onset of sporadic AD [5]. Several
similarities have been found between AD and PD, namely both
are characterized byneuronal loss and pathological aggregation
of proteins (b-amyloid and tau in AD and a-synuclein in PD)
whichpresumablyhavethecommonﬁbrillizationpathway[6,7].
Furthermore, theclinicalsymptomsofADandPDmayoverlapin
some patients [8]. The pathogenesis of dementia in PD is not
clear and it may be a mixture of Lewy Bodies as well as
Alzheimer's and vascular pathologies [9]. Therefore,APOE2 and
APOE4genotypeshavebeenproposedandtestedaspossiblePDD
susceptibility factors [10]. Although data from genome wide
association studies do not support this hypothesis, the role of
APOE4 in PDD development is still inconclusive [4,11]. The
purpose of this study was to determine the impact of APOE
genotypes on the risk of dementia among PD patients. The
present analysiswould be theﬁrst to be carried out on thePolish
population with the use of a wide range of neuropsychological
tests and Emre et al. criteria [12] to assess the cognitive
impairment in PD patients.2. Materials and methods
2.1. Subjects
The study population comprised of 237 patients of Caucasian
origin (123 males and 114 females), aged from 35 to 89 years
(64.23 9.97), diagnosed with PD according to the UK Parkin-
son's Disease Society Brain Bank Clinical Diagnostic Criteria
[13]. Diagnosis was conﬁrmed during follow-up visits (at least
two with levodopa response assessment). The subjects were
enrolledbetween January 2008andDecember 2010at two PolishTable 1 – Demographic and clinical characteristics of non-dem
patients.
Demographic and clinical data Parkinson's Disease pa
(n = 237)
M/F 123/114
Mean age  SD and range (years) 64.23  9.97
35–89
Age at disease onset and range (years) 57.42  11.07
28–87
Disease duration and range (years) 6.8  5.3
0.5–25
Daily levodopa dosage (mg) 724  441
(n = 228)
UPDRS (part II–IV) 35.0  18.6
(n = 215)
MMSE score 26.8  3.5
(n = 235)
Statistical analyses performed with:
* Fisher's test.
** Student's t-test.
*** Mann–Whitney's test.centers (Gdansk, Szczecin). Further investigations, including
the assessment of the severity of motor symptoms determined
by means of the Uniﬁed Parkinson's Disease Rating Scale
(UPDRS) (parts II–IV), were also undertaken. The exclusion
criteria consisted of clinical symptoms suggesting secondary
causes of Parkinson's Disease (drug-induced, vascular) or
atypical Parkinsonian syndromes (multiple system atrophy,
corticobasal syndrome and progressive supranuclear palsy).
Brain MRI was performed to exclude any vascular cause of PD.
The studywasapprovedby the relevant local ethics committees
and written informed consent obtained from the participants.
Based on the neuropsychological assessment described below,
the group was divided into two subgroups of non-demented PD
(nPDD, n = 164) and demented PD (PDD, n = 73). Demographic
and clinical data were collected according to a semi-structured
interview and medical documentation and are presented in
Table 1.
2.2. Neurological examination
Neurological examination was performed to conﬁrm the PD
diagnosis and exclude other symptoms suggesting atypical or
symptomatic cases. It consisted of the Uniﬁed Parkinson's
Disease Rating Scale (UPDRS; part II–IV), Hoehn–Yahr staging
and the Schwab-England activities of daily living scale.
2.3. Neuropsychological assessment
All assessments were conducted by experienced psycholo-
gists, who established examination procedures and their
standards before the onset of the study. Patients were
examined in the 'on state'. TheMini Mental State Examination
(MMSE) test with the age and education correctionwas used as
a screening tool. Patients had undergone a detailed neuropsy-
chological examination, including the Wechsler Adult Intelli-
gence Scale-Revised (WAIS-R), the Rey Auditory Verbal
Learning Test (RAVLT), the Benton Visual Retention Test
(BVRT), the Trail Making Test (TMT), the Rey-Osterrieth
Complex Figure Test (ROCF), the Verbal Fluency Test andented (nPDD) and demented (PDD) Parkinson's Disease
tients nPDD
(n = 164)
PDD
(n = 73)
p-value
86/78 37/36 0.888*
61.9  9.6
39–89
69.4  8.9
35–85
0.000004**
55.8  10.9
28–87
61.1  10.5
29–80
0.0005**
6.1  4.9
0.5–24
8.2  5.9
0.5–25
0.004**
697  442
(n = 157)
782  435
(n = 71)
0.034***
30.2  15.5
(n = 148)
45.6  20.5
(n = 67)
0.00000001***
28.1  1.9
(n = 163)
23.6  4.2
(n = 72)
0.00000001***
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Inventory Test (BDI) was performed to assess the severity of
depression. In addition, all the patients were examined by
means of Parkinson's Disease – Cognitive Rating Scale (PD-
CRS). The diagnosis of dementia was established in accor-
dance with the Emre et al.'s [12] criteria. Among 73 PDD
patients, there were 51 individuals with probable PDD and 22
patients with possible PDD.
2.4. Genetic study
Peripheral venous blood samples were collected from each
subject into tubes containing EDTA. It was followed by an
extraction of genomic DNA using a Genomic Mini AX Blood
SPIN (A&A Biotechnology, Poland). The concentration of every
sample of DNA was measured spectrophotometrically by
Nanodrop ND-1000 (Thermo Scientiﬁc, USA) and diluted to
20 ng/ml. To determine APOE polymorphisms (rs429358 and
rs7412) real-time PCR using pre-validated allelic discrimina-
tion TaqMan assays (rs429358 assay ID: C_3084793_20, rs7412
assay ID: C_904973_10; Life Technologies, USA)was carried out.
2.5. Statistical analysis
The distribution of samples was evaluated using the Shapiro–
Wilk test. According to data alignment with normal distribu-
tion, Student's t-test or Mann–Whitney's test was performed
to estimate the statistical differences between the groups.
Categorical variables' frequencies between the groups (geno-
types, alleles, sex etc.) were analyzed by the means of Fisher's
test. All p-values of less than 0.05 were considered statistically
signiﬁcant.3. Results
As shown in Table 1, several statistically signiﬁcant differ-
ences have been found between nPDD and PDD patients. The
mean age in PDD group was signiﬁcantly higher (69.4  8.9)
than in nPDD group (61.9  9.6, p = 0.000004). Moreover, PDD
patients were statistically 5 years older at the onset of the
disease compared to non-demented patients (p = 0.0005). The
disease duration was also longer among PDD patients
(p = 0.004), which supports the observation on the cumulative
prevalence of dementia in PD. Along with the progression of
the disease, the daily levodopa dosage has increased as well
(782  435 mg vs. 697  442 mg). This tendency is commonly
seen in everyday clinical practice. BothMMSE and UPDRS (part
II–IV) scores did show signiﬁcant differences among dement-
ed- and non-demented patients[5_TD$DIFF].Table 2 – APOE alleles' frequencies among Parkinson's Disease
APOE allele Parkinson's disease patients
(n = 237)
APOE*2 25 (0.0527)
APOE*3 397 (0.8376)
APOE*4 52 (0.1097)
P-value according to Fisher's test.3.1. APOE gene rs429358 polymorphism
Among 237 patients, 187 were wild type TT homozygous
(78.9%), 48 persons were CT heterozygous (20.3%), while 2
subjects were CC homozygous (0.8%). Among non-demented
Parkinson's Disease patients the most frequent genotype was
TT (132 patients – 80.5%), 31 were CT heterozygous (18.9%) and
one person was CC homozygous (0.6%). Demented patients
were mostly TT homozygous (55 patients – 75.3%) as well,
whereas 17 personswere heterozygous (23.3%) and onewas CC
homozygous (1.4%). No statistically signiﬁcant differences in
rs429358 genotype frequencies between patients with and
without dementia have been found.
3.2. APOE gene rs7412 polymorphism
The frequency of the rs7412 genotypes among Parkinson's
Disease patients was as follows: wild type CC homozygous –
212 subjects (89.5%), CT heterozygous – 25 subjects (10.5%).
However, no TT homozygous was determined during the
analysis. Among the 164 non-demented subjects 145 cases
were CC homozygous (88.4%), whilst the rest (11.6%) were CT
heterozygous. Among PDD patients 67 persons were CC
homozygous (91.8%). CT genotype was conﬁrmed among 6
patients (8.2%). No statistically signiﬁcant differences in rs7412
genotype frequencies between patients with and without
dementia have been found.
3.3. APOE alleles
Based on rs429358 and rs7412 polymorphisms APOE alleles
frequencies were assessed[11_TD$DIFF] and are presented in Table 2.
According to the performed analysis, APOE*3was described as
the most frequent allele in both nPDD and PDD groups. No
signiﬁcant correlation in the frequencies of APOE alleles
between Parkinson's Disease patients with or without demen-
tia was found.
4. DiscussionSeveral genetic risk factors of Parkinson's Disease have been
proposed, including a conﬁrmed Alzheimer's Disease risk
factor: APOE4, as well as APOE2. The aim of this study was to
investigatewhether PDDandnPDDpatients differ signiﬁcantly
in terms of APOE genotypes.
This study demonstrates no statistically signiﬁcant corre-
lation between APOE genotypes and dementia in Parkinson's
Disease. These results are consistent with Ezquerra et al., who
did not ﬁnd any correlation between APOE4 and PDD ( p = 0.36)patients.
nPDD patients
(n = 164)
PDD patients
(n = 73)
p-value
19 (0.0579) 6 (0.0411) 0.653
276 (0.8415) 121 (0.8288) 0.785
33 (0.1006) 19 (0.1301) 0.426
Table 3 – Review of the published studies on the impact of APOE genotypes on PDD.
Year Authors Number of
the subjects
Criteria for dementia Main ﬁndings
1996 Helisalmi et al. [17] nPDD = 15
PDD = 8
not deﬁned The APOE4 allele frequency for PDD higher than for
nPDD patients [p-value unknown].
2000 Harhangi et al. [10] nPDD = 81
PDD = 26
DSM III APOE2 allele strongly increased the risk of dementia
in patients with PD ( p < 0.007).
2004 Jasinska-Myga
et al. [18]
nPDD = 51
PDD = 53
MMSE APOE genotype and allele frequencies did not differ
between nPDD and PDD groups.
2005 Camicioli et al. [19] nPDD = 19
PDD = 28
Based on global impression of history
and, where available, MMSE
consideration.
[post-mortem study]
Of 12 subjects with an APOE4 allele, 9 (75%) became
demented compared with 19 of the 35 (54%)
subjects without an APOE4 allele ( p = 0.31).
2006 Mollenhauer et al.
[20]
nPDD = 23
PDD = 73
MMSE < 25 The distribution of the APOE genotypes in PDD and
nPDD groups was similar to that of controls.
2006 Pankratz [8] nPDD = 274
PDD = 50
MMSE A signiﬁcant increase in the risk for dementia given
the presence of an APOE4 allele (OR = 3.38; p = 0.002)
The presence of an APOE2 allele did not have a
signiﬁcant effect on the risk for dementia.
[Study with the exclusive focus on familial PD.]
2007 Papapetropoulos
et al. [21]
nPDD = 33
PDD = 39
Diagnosis made by a psychiatrist,
formal psychometric testing and/or
MMSE < 24.
An association between PDD and APOE4 (OR 1.7;
95% conﬁdence interval: 1.02–2.9; p = 0.04).
2007 Jasinska-Myga
et al. [16]
nPDD = 100
PDD = 98
ICD-10 and DSM-IV criteria, with
MMSE < 24 and cognitively related
disability determined by the Physical
Self-Maintenance Scale score.
Neuropsychological battery of tests to
assess verbal and nonverbal memory,
orientation, language, attention,
abstract reasoning, and visuospatial
ability.
Frequency of APOE alleles did not differ between the
groups with PDD and nPDD ( p = 0.84)
2008 Ezquera et al. [11] nPDD = 138
PDD = 86
Emre et al. No statistical signiﬁcant difference was detected
comparing the APOE4 genotypes frequency in PDD
with nPDD patients ( p = 0.36).
No difference was detected comparing the APOE 2
genotype frequencies PDD with nPDD patients
( p = 0.38).
2009 Williams-Gray
et al. [6]
nPDD = 88
PDD = 19
MMSE ≤ 24
and fulﬁllment of the DSM-IV criteria at
follow-up.
Eight of 31 individuals (26%) carrying the APOE4
allele developed dementia, vs. 11 of 76 (14%) non-
carriers; OR 2.06 (0.74–5.74, p = 0.16).
2010 Choi et al. [22] nPDD = 20
PDD = 23
DSM IV No signiﬁcant association between the APOE4
genotype and dementia.
2014 Monsell et al. [23] nPDD & PDD = 232 Clinical Dementia Rating Sum of Boxes
score (CDR-SB)
In subjects seen within 5 years of their PD
diagnosis, the odds of dementia were higher in
APOE4 carriers: OR = 5.15 (1.52–17.40, p = 0.008).
For those seen 5 + years after their diagnosis: OR
3.54 (1.27–9.92, p = 0.02).
2017 Huertas et al. [24] nPDD = 239
PDD = 59
Emre et al. The development of dementia was inﬂuenced by
the APOE4 allele (HR = 1.90; p = 0.03).
No association was found for the APOE2 allele.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 4 7 7 – 4 8 2480or APOE2 and PDD (p = 0.38) [11]. Furthermore, Ezquerra et al.,
reported no inﬂuence ofAPOE4 genotype on age at the onset of
the disease (p = 0.32). Although our own study made use of
similar diagnostic criteria methodology (to that of the
aforementioned study) in order to evaluate dementia in PD,
methodological differences need to be indicated. The Ezquerra
et al. study differs from our own in so far that RFLP genotyping
was performed, which is known to be less sensitive and
speciﬁc method than real-time PCR.
However, our results are inconsistent with Williams-Gray
et al., study [6]. Although no inﬂuence of APOE4 genotype on
Parkinson's Disease incidence rate was determined in theabovementioned analysis, a statistically signiﬁcant correlation
between APOE4 genotype and Parkinson's Disease Dementia
was found [OR 1.74 (1.36–2.23), p = 1  104[10_TD$DIFF] . In spite of a large
study population (4198 cases and 10066 controls), several
factors may impact the validity of the results, in particular the
heterogeneity of odds ratios between the analyzed studies.
Moreover, PDD cases in each analysiswere limited (average 39,
min.8–max.98). Additionally, the discrepancy between the
meta-analysis and our results may be explained by a different
methodology, particularly by the diagnostic criteria for
dementia. The research presented in the meta-analysis was
performed for 13 years (from 1994 to 2007); consequently,
n e u r o l o g i a i n e u r o ch i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 4 7 7 – 4 8 2 481differences are unavoidable (Emre et al., criteria were
published in 2007). Dementia in Williams-Gray's own study
was diagnosed according to MMSE score and DSM-IV criteria.
MMSE is a screeningmethodand is not recommended as a PDD
diagnostic criterion. The lack of adequate power of dementia
diagnostics by themeans ofMMSEhas also beennoted byMata
et al. [14]. Therefore, a range of psychometric tests has been
used in his research, including Trail Making Test (TMT) and
Hopkins Verbal Learning Test-Revised (HVLT-R). As a result,
the impact of APOE4 allele on lower performance across
multiple cognitive domains has been found. According to the
diagnostic criteria published in 2007, MMSE cannot be the only
test for dementia in Parkinson's Disease [13].
The APOE polymorphisms in the Polish population were
analyzed, among others, by Bednarska-Makaruk et al. [15].
Though the research comprised of randomly selected subjects,
the frequency of APOE alleles was similar to our study.
However, the distribution of APOE alleles among PDD and
nPDD in other studies on the Polish population was signiﬁ-
cantly different than in the presented research, both in PDD
and nPDD groups [16]. We do not know what was the exact
genotyping method in Jasińska-Myga et al.'s analysis.
The previous studies on the impact of APOE genotypes on
PDD have been presented in Table 3. The discrepancy in the
published studiesmay be attributed to several factors: namely
sample size limitations, the heterogeneity of the study
populations and different diagnostics criteria for PDD. In our
study a detailed neuropsychological testing and Emre et al.
criteria was used in order to assess cognitive impairment in PD
patients. Thus, it has enabled a higher sensitivity in dementia
diagnostics.
The impact of APOE4 genotype on dementia in pure
synucleinopathies including Parkinson'sDiseasewas explored
by Tsuang et al., who enrolled 640 demented cases to their
study [4]. Within the case group 81 patients were diagnosed
with PDD according to UK PD SBB and Emre et al., criteria. Real-
time PCR using TaqMan assays was carried out to determine
APOE alleles The control subjects were autopsied and a clinical
evaluation was made within 3 years of their death to exclude
neuropathological changes. Statistically signiﬁcant impact of
the APOE4 genotype on PDD was evaluated (p = 1.94  105).
Additionally, the results show an association between APOE4
allele and Alzheimer Disease, Lewy Body Disease with
Alzheimer Disease neuropathologic changes (LBD-AD) and
pure DLB (p-DLB) as well. Although, APOE4 is a well-
established risk factor for AD and DLB-AD, the impact of
APOE4 on PDD and p-DLB suggests other than amyloidogenic
mechanisms [4]. Nevertheless, APOE4 allele frequency was
lower in PDD group (19.1%) than in other synucleinopathies,
for instance in the group with dementia with Lewy bodies
(31.9%, p = 0.01).
Several studies have established a signiﬁcant correlation
between Alzheimer's Disease and APOE4 [25–27]. Up to 65% of
all pathologically conﬁrmed AD cases carry at least one APOE4
allele and 12–15% are homozygous for APOE4 compared to 1–
3% of healthy individuals [28]. However, the research on the
impact of APOE2 genotype on AD are inconclusive [29,30]. The
similarity between PD and AD pathogenesis, involving APOE
polymorphisms as well, may not be as clear as it has been
assumed. Although the conclusions drawn that the frequentco-occurrence of a-synuclein, amyloid, and tau protein
suggest common pathomechanisms for PD and AD, it is
elusive to determine whether these lesions emerge from the
same background mechanisms [10,31,32]. The outcome possi-
bly represents a collision of two or more processes. Further-
more, the unclear situation is further impeded by the
overlapping symptoms of AD and PD/DLB, all of them causing
movement disorders and dementia [33]. Similarly, several
studies have examined APOE in DLB based only on clinical
criteria, thus no distinction between LBD-AD and pDLB have
beenmade [4]. Therefore, well-established diagnostics criteria,
especially concerning dementia in respective neurodegenera-
tive diseases, are vital.
In summary, we have shown no statistically signiﬁcant
interaction between APOE genotypes (based on rs429358 and
rs7412 polymorphisms) and the onset of Parkinson's Disease
Dementia. The study population was enrolled at more than
one clinic center and distinguishes by its sample size. The
limitation of our study could be the lack of a pathologic
conﬁrmationof the diagnosis. Nevertheless, our study is one of
the few that has used a full battery of neuropsychological tests
and the ﬁrst one on the Polish population which has assessed
cognitive decline in Parkinson's Disease patients according to
PDD criteria proposed by Emre et al. In our view these uniﬁed
criteria allow for the diagnosis of dementia in Parkinson's
Disease patients in more reliable way than before.
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